PA Media on MSN7h
GSK lifts long-term sales targets on new drug pipeline
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and ...
GlaxoSmithKline (GSK) Gets a Hold from UBS
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
DPA International on MSN6h
Annual core operating profit increases for British pharma GSK
Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £23.55. The ...
American Association of Individual Investors4h
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...
FTSE 100 climbs after temporary easing of Trump tariff fears
The biggest fallers on the FTSE 100 were Diageo, down 92.5p to 2235p, DCC, down 195p to 5300p, Croda, down 103p to 3110p, ...
GSK shares rise over 5% after Q4 results
GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.
New9h
Vehicle Advertising Company Carvertise Rolling Through New Orleans
Advertisers are turning to creative strategies to capture attention ahead of the showdown between the Philadelphia Eagles and ...
GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
FiercePharma4h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...